Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- YMAB
- Price
- 4.83
- Stock movement up
- +0.48 (11.03%)
- Company name
- Y mAbs Therapeutics
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 216.33M
- Ent value
- 176.70M
- Price/Sales
- 2.56
- Price/Book
- 2.34
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -20.06%
- 1 year return
- -64.97%
- 3 year return
- -29.90%
- 5 year return
- -29.20%
- 10 year return
- -
Last updated: 2025-04-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
YMAB does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 2.56 |
| Price to Book | 2.34 |
| EV to Sales | 2.09 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 44.79M |
| EPS (TTM) | -0.53 |
| FCF per share (TTM) | -0.49 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 84.55M |
| Gross profit (TTM) | 75.11M |
| Operating income (TTM) | -28.46M |
| Net income (TTM) | -23.86M |
| EPS (TTM) | -0.53 |
| EPS (1y forward) | -0.54 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 88.83% |
| Operating margin (TTM) | -33.66% |
| Profit margin (TTM) | -28.22% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 68.12M |
| Net receivables | 19.92M |
| Total current assets | 99.06M |
| Goodwill | 0.00 |
| Intangible assets | 2.37M |
| Property, plant and equipment | 1.13M |
| Total assets | 120.92M |
| Accounts payable | 7.88M |
| Short/Current long term debt | 1.07M |
| Total current liabilities | 25.29M |
| Total liabilities | 28.49M |
| Shareholder's equity | 92.43M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -21.88M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -21.88M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -25.82% |
| Return on Assets | -19.74% |
| Return on Invested Capital | -25.60% |
| Cash Return on Invested Capital | -23.48% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 4.55 |
| Daily high | 4.88 |
| Daily low | 4.39 |
| Daily Volume | 214K |
| All-time high | 54.26 |
| 1y analyst estimate | 20.64 |
| Beta | 0.67 |
| EPS (TTM) | -0.53 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 5 May 2025 |
Downside potential
Loading...
Downside potential data
| YMAB | S&P500 | |
| Current price drop from All-time high | -91.10% | -12.89% |
| Highest price drop | -94.78% | -56.47% |
| Date of highest drop | 22 Mar 2023 | 9 Mar 2009 |
| Avg drop from high | -52.84% | -11.07% |
| Avg time to new high | 52 days | 12 days |
| Max time to new high | 1084 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
216.33M
Marketcap category
Small-cap
Description
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
Employees
100
Website
Investor relations
-
SEC filings
CEO
Claus Juan Møller-San Pedro
Country
USA
City
New York
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page